logo
BlackRock TCP Capital Corp. to Report Second Quarter Ended June 30, 2025 Financial Results on August 7, 2025

BlackRock TCP Capital Corp. to Report Second Quarter Ended June 30, 2025 Financial Results on August 7, 2025

Business Wire2 days ago
SANTA MONICA, Calif.--(BUSINESS WIRE)--BlackRock TCP Capital Corp. (NASDAQ: TCPC) announced today that it will report its financial results for the second quarter ended June 30, 2025 on Thursday, August 7, 2025, prior to the opening of the financial markets.
BlackRock TCP Capital Corp. will also host a conference call at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) on Thursday, August 7, 2025, to discuss its financial results.
All interested parties are invited to participate in the conference call by dialing (833) 470-1428; international callers should dial (404) 975-4839. All participants should reference the access code 311460. The conference call will be webcast simultaneously in the investor relations section of TCPC's website at http://investors.tcpcapital.com. An archived replay of the call will be available approximately two hours after the live call, through August 14, 2025. For the replay, please visit https://investors.tcpcapital.com/events-and-presentations or dial (866) 813-9403. For international replay, please dial (929) 458-6194. For all replays, please reference access code 746213.
ABOUT BLACKROCK TCP CAPITAL CORP.:
BlackRock TCP Capital Corp. (NASDAQ: TCPC) is a specialty finance company focused on direct lending to middle-market companies as well as small businesses. TCPC lends primarily to companies with established market positions, strong regional or national operations, differentiated products and services and sustainable competitive advantages, investing across industries in which it has significant knowledge and expertise. TCPC's investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. TCPC is a publicly traded business development company, or BDC, regulated under the Investment Company Act of 1940 and is externally managed by its advisor, a wholly owned, indirect subsidiary of BlackRock, Inc. For more information, visit www.tcpcapital.com.
Prospective investors considering an investment in BlackRock TCP Capital Corp. should consider the investment objectives, risks and expenses of the Company carefully before investing. This information and other information about the Company are available in the Company's filings with the Securities and Exchange Commission ("SEC"). Copies are available on the SEC's website at www.sec.gov and the Company's website at www.tcpcapital.com. Prospective investors should read these materials carefully before investing.
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of management of the Company at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, changes in general economic conditions or changes in the conditions of the industries in which the Company makes investments, risks associated with the availability and terms of financing, changes in interest rates, availability of transactions, and regulatory changes. Certain factors that could cause actual results to differ materially from those contained in the forward-looking statements are included in the 'Risk Factors' section of the Company's Form 10-K for the year ended December 31, 2024, and the Company's subsequent periodic filings with the SEC. Copies are available on the SEC's website at www.sec.gov and the Company's website at www.tcpcapital.com. Forward-looking statements are made as of the date of this press release and are subject to change without notice. The company has no duty and does not undertake any obligation to update or revise any forward-looking statements based on the occurrence of future events, the receipt of new information, or otherwise.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target
Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target

Yahoo

time37 minutes ago

  • Yahoo

Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company secured accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) on July 2, 2025, marking a significant progress in the treatment of relapsed or refractory multiple myeloma in patients who have undergone four or more prior therapies. The approval adds depth to the company's late-stage pipeline. Moreover, it enhances the company's long-term growth trajectory in a high-need, underserved segment of the cancer market. A medical professional holding vials of biotechnology therapeutic candidate. On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 price target. Although Regeneron has faced recent headwinds, particularly around Eylea, Schott expects those pressures to ease. He points to patient affordability issues and competitive dynamics as near-term hurdles, but believes the enhanced Eylea HD formulation and expanded copay assistance programs should help stabilize sales. Offsetting some of this softness is the continued strength of Dupixent, which Schott sees as a key growth engine, especially as new indications expand its market reach. Looking ahead, Schott views the setup for Regeneron shares as compelling. With a strong balance sheet and growing contributions from Dupixent, he sees room for upside even without relying on near-term pipeline catalysts. However, potential updates, including LAG-3 data in melanoma and further clarity on Eylea, could serve as meaningful valuation drivers. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is a biotechnology company focused on discovering, developing, and distributing innovative therapies that address serious and life-threatening diseases. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

MongoDB (MDB) Gets Vote of Confidence from William Blair Amid Market Skepticism
MongoDB (MDB) Gets Vote of Confidence from William Blair Amid Market Skepticism

Yahoo

time37 minutes ago

  • Yahoo

MongoDB (MDB) Gets Vote of Confidence from William Blair Amid Market Skepticism

MongoDB Inc. (NASDAQ:MDB) is one of the 11 best debt-free stocks to invest in right now. In early June, William Blair analyst Jason Ader reiterated his Buy rating on MongoDB without a price target. The analyst maintained a constructive view despite heightened concerns around competition in the database market. Ader acknowledges that competitors like Postgres and other relational database solutions are eating into its pie, but argues that MongoDB's core advantages, particularly in scalability, developer experience, and flexibility, give it a durable edge. He believes these strengths will allow MongoDB to continue gaining share in the operational database segment, which is expanding at a healthy 10% annual rate. A database administrator managing a large database, ensuring the client's data is secure. While recent market sentiment has turned cautious, partly due to perceived competitive risks, Ader sees the valuation reset as excessive, offering a more favourable setup for long-term investors. He expects growth to reaccelerate over the medium term, supported by increased go-to-market investments and expanding AI-related workloads, areas where MongoDB is well-positioned. MongoDB Inc. (NASDAQ:MDB) develops database software and provides open-source database platforms for automating, monitoring, and deploying data. While we acknowledge the potential of MDB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and . Disclosure: None. This article is originally published at Insider Monkey.

Mizuho Downgrades CoreWeave (CRWV) Stock to Neutral
Mizuho Downgrades CoreWeave (CRWV) Stock to Neutral

Yahoo

timean hour ago

  • Yahoo

Mizuho Downgrades CoreWeave (CRWV) Stock to Neutral

CoreWeave, Inc. (NASDAQ:CRWV) is one of the Top 10 Software and Technology Stocks to Buy Now. Mizuho downgraded the company's stock to 'Neutral' from 'Outperform' with a price objective of $150, up from the prior target of $70, as reported by The Fly. The rating change comes after the company's announcement that it agreed to acquire Core Scientific, combining 2 significant players in the AI infrastructure space. An engineer wearing virtual reality goggles programming the company's video cloud and software. The firm sees this acquisition positively, noting that it allows CoreWeave, Inc. (NASDAQ:CRWV) to verticalize the infrastructure supply chain while, at the same time, driving significant cost synergies and allowing for more financing flexibility. Mizuho views CoreWeave, Inc. (NASDAQ:CRWV)'s stock as fairly valued at the current levels, with risks around customer concentration. The acquisition accelerates CoreWeave, Inc. (NASDAQ:CRWV)'s strategy to deploy AI and HPC workloads at scale. While this company will gain greater control over a critical power footprint and optionality for future power capacity, Core Scientific's data center development capabilities tend to complement and augment CoreWeave, Inc. (NASDAQ:CRWV)'s extensive expertise in power procurement, construction, and site management for the infrastructure assets. While we acknowledge the potential of CRWV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store